

PRECEPTORSHIP PROGRAMME

Gastric Cancer

**ESMO
PRECEPTORSHIP**

**VALENCIA SPAIN
28-29 OCTOBER 2022**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

Chairs:

Florian Lordick, Germany

Elizabeth Smyth, United Kingdom

ESMO PRECEPTORSHIP PROGRAMME GASTRIC CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Valencia, Spain
28-29 October 2022

CO-CHAIRS: Florian Lordick, Germany
Elizabeth Smyth, United Kingdom

SPEAKERS: Fátima Carneiro, Portugal
Andrés Cervantes, Spain
Christelle de la Fouchardière, France
Mario Dinis-Ribeiro, Portugal
Tania Fleitas, Spain
Maria Hawkins, United Kingdom
Radka Obermannová, Czech Republic
Guillaume Piessen, France

LEARNING OBJECTIVES

- To learn about the fundamentals of epidemiology, aetiology, pathogenesis, molecular events and immune biology of gastric and esophago-gastric junction cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric cancer
- To learn about advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 28 October 2022

09:00-09:10 10'	Opening and welcome	
10'	Welcome from ESMO and introduction	Florian Lordick, DE Elizabeth Smyth, UK
09:10-11:25 135'	SESSION 1 Epidemiology, pathology and diagnosis of gastric cancer	Chair: Elizabeth Smyth, UK
30'	Epidemiology (including GE junction tumours)	Andrés Cervantes, ES
45'	Pathology, carcinogenesis and its clinical impact	Fátima Carneiro, PT
30'	How to establish the clinical diagnosis of gastric cancer. Focus on endoscopic imaging, staging, and treatment of early gastric cancer	Mario Dinis-Ribeiro, PT
15'	A case discussion demonstrating the clinical impact of pathology	Tania Fleitas, ES
15'	Discussion	Faculty
11:25-11:55	Coffee break	
11:55-13:25 90'	SESSION 2 Surgical, adjuvant and neoadjuvant treatment of gastric cancer	Chair: Florian Lordick, DE
30'	Surgery for gastric and EG junction cancer, primary, palliative - where and when?	Guillaume Piessen, FR
30'	Perioperative treatment for gastric cancer: State of the art and current controversies	Elizabeth Smyth, UK
20'	Radiation therapy for gastric cancer, and oesophago-gastric junction cancer	Maria Hawkins, UK
10'	Discussion	Faculty
13:25-14:30	Lunch	
14:30-15:10 40'	SESSION 3 Guidelines	Chair: Elizabeth Smyth, UK
30'	New ESMO guidelines on oesophageal and gastric cancer – Major changes from last versions	Radka Obermannová, CZ
10'	Discussion	Faculty
15:10-15:30	Coffee break	
15:30-17:30 120'	SESSION 4 Advanced disease	Chair: Elizabeth Smyth, UK
30'	Sequential chemotherapy (doublet, triplet, elderly patients, sequences, anti-angiogenic therapy, oral chemotherapy)	Tania Fleitas, ES
40'	Biologically targeted treatment (HER2, Claudin 18.2, FGFR2, and beyond)	Florian Lordick, DE
40'	Immunotherapy	Christelle de la Fouchardière, FR
10'	Discussion	Faculty
20:30	Dinner	

Saturday, 29 October 2022

09:00-10:30 90'	SESSION 5 Case discussion based on ESMO Clinical Practice Guidelines I	Chair: Florian Lordick, DE
90'	Participants clinical case discussion (6x15')	Faculty
10:30-11:00	Coffee break	
11:00-12:30 90'	SESSION 6 Case discussion based on ESMO Clinical Practice Guidelines II	Chair: Elizabeth Smyth, UK
90'	Participants clinical case discussion (6x15')	Faculty
12:30-12:50 20'	Future outlook, conclusion and farewell	Florian Lordick, DE Elizabeth Smyth, UK
12:50-14:00	Lunch	

Note: Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion